Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Melanoma × alovudine × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 3 Neoplasms 2 Central Nervous System Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Oligodendroglioma 1 Melanoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Disease 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1

Interventions

pembrolizumab 91 Nivolumab 57 Ipilimumab 55 Cyclophosphamide 52 Vemurafenib 28 fludarabine 27 aldesleukin 25 Interleukin-2 25 fludarabine phosphate 21 trametinib 20 dabrafenib 17 Temozolomide 14 Biopsy 14 Cisplatin 13 spartalizumab 12 atezolizumab 12 Carboplatin 11 cobimetinib 10 Paclitaxel 10 Introns 10 CTLA-4 Antigen 10 poly ICLC 9 binimetinib 9 Specimen Handling 9 Radiotherapy 9 Radiosurgery 9 MART-1 Antigen 9 tremelimumab 8 incomplete Freund's adjuvant 8 Radiation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02891616 2019-07-17

18F-FLT PET Imaging in Patients With Advanced Melanoma

Washington University School of Medicine

Phase 1 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡